

Strain	Group	Pre-Booster (40 months of age)		Post dose 1		Post dose 2	
		Percentage SBA $\geq$ 1:4 (95% C.I.)	n/N	Percentage SBA $\geq$ 1:4 (95% C.I.)	n/N	Percentage SBA $\geq$ 1:4 (95% C.I.)	n/N
44/76 - SL	4CMenB	36(13 – 65)	5/14	100(77-100)	14/14		
	rMenB	14(2 – 43)	2/14	100(75-100)	13/13		
	Control	3(0 – 13)	1/39	72(55-85)	28/39	100(88-100)	30/30
5/99	4CMenB	100(77-100)	14/14	100(77-100)	14/14		
	rMenB	93(66-100)	13/14	100(77-100)	14/14		
	Control	0(0-9)	0/40	87(73-96)	34/39	100(89-100)	31/31
NZ98/254	4CMenB	14(2-43)	2/14	93(66-100)	13/14		
	rMenB	0(0-22)	0/15	21(5-51)	3/14		
	Control	0(0-9)	0/39	23(11-39)	9/39	90(74-98)	28/31
M10713	4CMenB	79(49-95)	11/14	93(66-100)	13/14		
	rMenB	29(8-58)	4/14	69(39-91)	9/13		
	Control	53(36-68)	21/40	62(45-77)	24/39	72(53-87)	21/29
UK P1.7-2,4	4CMenB	69(39-91)	9/13	100(75-100)	13/13		
	rMenB	0(0-23)	0/14	69(39-91)	9/13		
	Control	14(5-29)	5/37	65(47-80)	24/37	100(88-100)	29/29
GB101	4CMenB	69(39-91)	9/13	100(75-100)	13/13		
	rMenB	50(23-77)	7/14	100(75-100)	13/3		
	Control	62(45-78)	23/37	100(91-100)	37/37	100(88-100)	29/29
GB355	4CMenB	8(0-36)	1/13	31(9-61)	4/13		
	rMenB	7(0-34)	1/14	8(0-36)	1/13		
	Control	0(0-9)	0/37	11(3-25)	4/37	11(2-28)	3/28
GB364	4CMenB	85(55-98)	11/13	92(64-100)	12/13		
	rMenB	43(18-71)	6/14	85(55-98)	11/13		
	Control	46(29-63)	17/37	59(42-75)	22/37	89(72-98)	25/28

Supplementary Table 3: The percentage of participants with serum bactericidal titers (hSBA) $\geq$ 1:4 and the 95% confidence intervals (C.I.). Analysis performed on intention to treat population. n = number of participants with SBA titres $\geq$ 1:4, N= number of participants in group included in intention to treat analysis at the specified study visit.